Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 6 | 3 |
| List of Figures | 9 | 2 |
| Sleep Disorders Market: Introduction | 11 | 2 |
| GBI Research Report Guidance | 12 | 1 |
| Sleep Disorders Market to 2017: Market Overview | 13 | 10 |
| Introduction | 13 | 1 |
| Revenue Forecasts for the Sleep Disorder Therapeutics Market | 14 | 1 |
| Revenue | 14 | 1 |
| Annual Cost of Treatment (ACT) | 15 | 2 |
| Treatment Usage Patterns | 17 | 2 |
| Diseased Population | 19 | 1 |
| Treatment Seeking Population | 20 | 1 |
| Diagnosis Population | 21 | 1 |
| Prescription Population | 22 | 1 |
| Sleep Disorders Market to 2017: Geographical Landscape | 23 | 28 |
| Revenue Analysis by Geography | 23 | 2 |
| The US | 25 | 1 |
| Revenue | 25 | 1 |
| Annual Cost of Treatment | 26 | 2 |
| Treatment Usage Patterns | 28 | 2 |
| Diseased Population | 30 | 1 |
| Treatment Seeking Population | 31 | 2 |
| Diagnosis Population | 33 | 1 |
| Prescription Population | 34 | 1 |
| Top Five Countries of Europe | 35 | 1 |
| Revenue | 35 | 1 |
| Annual Cost of Treatment | 36 | 1 |
| Treatment Usage Patterns | 37 | 2 |
| Diseased Population | 39 | 1 |
| Treatment Seeking Population | 40 | 1 |
| Diagnosis Population | 41 | 1 |
| Prescription Population | 42 | 1 |
| Japan | 43 | 1 |
| Revenue | 43 | 1 |
| Annual Cost of Treatment | 44 | 1 |
| Treatment Usage Patterns | 45 | 2 |
| Diseased Population | 47 | 1 |
| Treatment Seeking Population | 48 | 1 |
| Diagnosis Population | 49 | 1 |
| Prescription Population | 50 | 1 |
| Sleep Disorders Market: Therapeutic Landscape | 51 | 41 |
| Insomnia Therapeutics Market | 51 | 1 |
| Introduction | 51 | 1 |
| Revenue | 52 | 1 |
| Annual Cost of Treatment | 53 | 1 |
| Treatment Usage Patterns | 54 | 2 |
| Diseased Population | 56 | 1 |
| Treatment Seeking Population | 57 | 1 |
| Diagnosis Population | 58 | 1 |
| Prescription Population | 59 | 1 |
| Drivers and Barriers for the Insomnia Therapeutics Market | 60 | 1 |
| Drivers for the Insomnia Therapeutics Market | 60 | 1 |
| Barriers for the Insomnia Therapeutics Market | 61 | 1 |
| Restless Leg Syndrome Therapeutics Market | 61 | 1 |
| Introduction | 61 | 1 |
| Revenue | 62 | 1 |
| Annual Cost of Treatment | 63 | 1 |
| Treatment Usage Patterns | 64 | 2 |
| Diseased Population | 66 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosis Population | 68 | 1 |
| Prescription Population | 69 | 1 |
| Drivers and Barriers for the Restless Leg Syndrome Therapeutics Market | 70 | 1 |
| Drivers for the Restless Leg Syndrome Therapeutics Market | 70 | 1 |
| Barriers for the Restless Leg Syndrome Therapeutics Market | 71 | 1 |
| Narcolepsy Therapeutics Market | 71 | 1 |
| Introduction | 71 | 1 |
| Revenue | 72 | 1 |
| Annual Cost of Treatment | 73 | 1 |
| Treatment Usage Patterns | 74 | 2 |
| Diseased Population | 76 | 1 |
| Treatment Seeking Population | 77 | 1 |
| Diagnosis Population | 78 | 1 |
| Prescription Population | 79 | 1 |
| Drivers and Barriers for the Narcolepsy Therapeutics Market | 80 | 1 |
| Drivers for the Narcolepsy Therapeutics Market | 80 | 1 |
| Barriers for the Narcolepsy Therapeutics Market | 81 | 1 |
| Sleep Apnea Therapeutics Market | 81 | 1 |
| Introduction | 81 | 1 |
| Revenue | 82 | 1 |
| Annual Cost of Treatment | 83 | 1 |
| Treatment Usage Patterns | 84 | 2 |
| Diseased Population | 86 | 1 |
| Treatment Seeking Population | 87 | 1 |
| Diagnosed Population | 88 | 1 |
| Prescription Population | 89 | 1 |
| Drivers and Barriers for the Sleep Apnea Therapeutics Market | 90 | 1 |
| Drivers for the Sleep Apnea Therapeutics Market | 90 | 1 |
| Barriers for the Sleep Apnea Therapeutics Market | 91 | 1 |
| Sleep Disorders Market to 2017: Pipeline Analysis | 92 | 12 |
| Introduction | 92 | 1 |
| Research and Development Pipeline Sleep Disorders | 93 | 1 |
| Insomnia Pipeline Analysis | 93 | 1 |
| Introduction | 93 | 1 |
| Insomnia Therapeutics Market Pipeline Assessment by Clinical Phase of Development | 94 | 1 |
| Filed Molecules | 95 | 1 |
| Phase III | 95 | 1 |
| Phase II | 96 | 1 |
| Phase I | 97 | 1 |
| Preclinical Phase | 97 | 1 |
| Discovery Phase | 97 | 1 |
| Restless Leg Syndrome Therapeutics Market: Pipeline Analysis | 98 | 1 |
| Introduction | 98 | 1 |
| Narcolepsy Therapeutics Market Pipeline Assessment by Clinical Phase of Development | 99 | 1 |
| Narcolepsy Therapeutics Market Pipeline Analysis | 100 | 1 |
| Introduction | 100 | 1 |
| Narcolepsy Therapeutics Market Pipeline Assessment by Clinical Phase of Development | 101 | 1 |
| Sleep Apnea Therapeutics Market Pipeline Analysis | 102 | 1 |
| Introduction | 102 | 1 |
| Sleep Apnea Therapeutics Market Pipeline Assessment by Clinical Phase of Development | 103 | 1 |
| Sleep Disorder Market to 2016: Competitive Landscape | 104 | 23 |
| Overview | 104 | 1 |
| Competitive Profiling | 104 | 1 |
| Sanofi-Aventis | 104 | 1 |
| Company Overview | 104 | 1 |
| Marketed Products | 104 | 3 |
| King Pharmaceuticals, Inc. | 107 | 1 |
| Company Overview | 107 | 1 |
| Marketed Products | 107 | 1 |
| Questcor Pharmaceuticals, Inc. | 108 | 1 |
| Company Overview | 108 | 1 |
| Marketed Products | 108 | 1 |
| Novartis | 109 | 1 |
| Company Overview | 109 | 1 |
| Marketed Products | 109 | 2 |
| GlaxoSmithKline plc | 111 | 1 |
| Company Overview | 111 | 1 |
| Marketed Products | 111 | 2 |
| Pfizer | 113 | 1 |
| Company Overview | 113 | 1 |
| Marketed Products | 113 | 2 |
| Boehringer Ingelheim | 115 | 1 |
| Company Overview | 115 | 1 |
| Marketed Products | 115 | 4 |
| Cephalon Pharmaceuticals | 119 | 1 |
| Company Overview | 119 | 1 |
| Marketed Products | 119 | 2 |
| Schwarz Pharma | 121 | 1 |
| Company Overview | 121 | 1 |
| Marketed Products | 121 | 4 |
| Mylan Pharma | 125 | 1 |
| Company Overview | 125 | 1 |
| Marketed Products | 125 | 2 |
| Sleep Disorders Market to 2017: M&A Landscape | 127 | 9 |
| Sleep Disorders Market | 127 | 1 |
| Overview: Deals by Type | 127 | 1 |
| Deals by Year | 128 | 1 |
| Mergers and Acquisitions | 128 | 1 |
| Overview | 128 | 1 |
| Meda Acquires Commercialization Rights of Sublinox and OX-NLA from Orexo | 128 | 1 |
| Eli Lilly Acquires Hypnion | 129 | 1 |
| Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical | 129 | 1 |
| Sciele Pharma Acquires Alliant Pharmaceuticals | 130 | 1 |
| Jazz Pharmaceuticals Acquires Orphan Medical | 130 | 1 |
| Paul Royalty Acquires US Royalty Rights of Estorra from Aventis | 130 | 2 |
| Licensing Agreements | 132 | 1 |
| GlaxoSmithKline (GSK) and Actelion Pharmaceuticals | 132 | 1 |
| Purdue Pharma Enters into License Agreement with Transcept Pharmaceuticals | 132 | 1 |
| Neurocrine Biosciences Enters into Licensing Agreement with Dainippon Sumitomo Pharma | 133 | 1 |
| Eli Lilly Enters into Licensing Agreement with Merck | 133 | 1 |
| ECR Pharmaceuticals Enters into License Agreement with NovaDel Pharma | 133 | 1 |
| Vanda Enters into Licensing Agreement with Bristol-Myers Squibb | 134 | 1 |
| Co-Development Strategies | 135 | 1 |
| Sleep Disorders Market: Appendix | 136 | 6 |
| Market Definition | 136 | 1 |
| Abbreviations | 136 | 1 |
| Research Methodology | 137 | 4 |
| Coverage | 137 | 1 |
| Secondary Research | 137 | 1 |
| Forecasting | 138 | 1 |
| Epidemiology-based Forecasting | 138 | 2 |
| Primary Research | 140 | 1 |
| Expert Panels | 140 | 1 |
| Contact Us | 140 | 1 |
| Disclaimer | 141 | 1 |
| Sources | 141 | 1 |